Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sigma-Aldrich posts 15% rise in Q4 net profit
Revenue increased 5% to $610m including 2% points from acquisitions, the company repoted. The company’s research-chemicals segment, its biggest contributor to the top line, reported sales were up
Revenue increased 5% to $610m including 2% points from acquisitions, the company repoted. The company’s research-chemicals segment, its biggest contributor to the top line, reported sales were up
The Phase I single ascending dose trials were intended to evaluate the safety, tolerability and pharmacokinetics of each therapeutic candidate in healthy adult volunteers. The company is conducting
Anatabloc is a dietary supplement that contains active dietary ingredients, anatabine citrate and Vitamins A and D3, designed to provide anti-inflammatory support. The study entitled "A Multi-Site, Double-Blind,
According to the collaboration, Genmab creates novel human antibodies to three targets identified by Lundbeck. Lundbeck has access to Genmab’s antibody creation and development capabilities, including its fully
Pfizer manufactured both drugs and they were marketed in the US by Akrimax Rx Products under the Akrimax Pharmaceuticals brand. The expiration dates on these contraceptives range from
LibiGel, a testosterone gel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. LibiGel, when applied once-daily
The partnership between PPD and NHS Research Scotland (NRS) will work to further minimize study start-up times, streamline regulatory approval processes and increase the number of patients recruited
The randomized double-blind placebo-controlled parallel group AssessmenT of Delivery of Drug via A Novel Device to the IntRanasal Cavity for MiGraine PatiEnTs (TARGET) study will include around 200
Catalyst’s intellectual property is a method of treating Tourette Syndrome using GABA aminotransferase inhibitor drugs, including CPP-109 and CPP-115. The method increases presynaptically stored GABA, and enhance GABA
ATS907 is a Rho kinase (ROCK)-selective inhibitor in development as a next-generation eye drop for the reduction of elevated intraocular pressure (IOP) in primary open angle glaucoma and